These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12504264)

  • 41. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
    Volavka J; Czobor P; Nolan K; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Lieberman JA
    J Clin Psychopharmacol; 2004 Apr; 24(2):225-8. PubMed ID: 15206671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013.
    Ponizovsky AM; Marom E; Ben-Laish M; Barash I; Weizman A; Schwartzberg E
    Isr J Health Policy Res; 2016; 5():16. PubMed ID: 27307984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
    Vuk A; Kuzman MR; Baretic M; Osvatic MM
    Psychiatr Danub; 2017 Jun; 29(2):121-135. PubMed ID: 28636569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risperidone versus other atypical antipsychotic medication for schizophrenia.
    Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
    Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
    Moisan J; Grégoire JP
    Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine.
    Bunker MT; Marken PA; Schneiderhan ME; Ruehter VL
    J Child Adolesc Psychopharmacol; 1997; 7(1):65-9. PubMed ID: 9192542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
    J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of antipsychotic therapy on serum lipids: a comprehensive review.
    Meyer JM; Koro CE
    Schizophr Res; 2004 Sep; 70(1):1-17. PubMed ID: 15246458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weight gain associated with antipsychotic drugs.
    Ganguli R
    J Clin Psychiatry; 1999; 60 Suppl 21():20-4. PubMed ID: 10548138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.
    Nasrallah HA; White T; Nasrallah AT
    Am J Geriatr Psychiatry; 2004; 12(4):437-9. PubMed ID: 15249282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocław].
    Magdalan J; Wasyko-Smolarek M; Antończyk A; Kochman K; Przewłocki M; Porebska B
    Przegl Lek; 2004; 61(4):392-6. PubMed ID: 15521612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.
    Gaviria AM; Franco JG; Aguado V; Rico G; Labad J; de Pablo J; Vilella E
    PLoS One; 2015; 10(10):e0139403. PubMed ID: 26427051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
    Bitter I; Czobor P; Dossenbach M; Volavka J
    Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
    Dias Alves M; Micoulaud-Franchi JA; Simon N; Vion-Dury J
    J Clin Psychopharmacol; 2018 Dec; 38(6):555-562. PubMed ID: 30247179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2000; (2):CD001359. PubMed ID: 10796640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review.
    Taylor DM; Young C; Paton C
    J Clin Psychiatry; 2003 Jan; 64(1):30-4. PubMed ID: 12590620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
    Ren XS; Kazis LE; Lee AF; Huang YH; Hamed A; Cunningham F; Herz L; Miller DR
    Schizophr Res; 2005 Sep; 77(2-3):167-77. PubMed ID: 15894460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.